157 related articles for article (PubMed ID: 31291209)
1. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jul; 25(4):290-297. PubMed ID: 31291209
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants.
Preskorn SH
J Psychiatr Pract; 2020 Jan; 26(1):46-51. PubMed ID: 31913969
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics.
Preskorn SH
J Psychiatr Pract; 2019 Nov; 25(6):461-465. PubMed ID: 31821222
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 May; 25(3):206-211. PubMed ID: 31083033
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 Mar; 25(2):118-127. PubMed ID: 30849059
[TBL] [Abstract][Full Text] [Related]
7. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.
Preskorn SH
J Psychiatr Pract; 2018 Sep; 24(5):341-347. PubMed ID: 30427821
[TBL] [Abstract][Full Text] [Related]
8. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jan; 25(1):34-40. PubMed ID: 30633730
[TBL] [Abstract][Full Text] [Related]
9. Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them.
Preskorn SH
J Psychiatr Pract; 2018 Jul; 24(4):261-268. PubMed ID: 30427809
[TBL] [Abstract][Full Text] [Related]
10. Consistency of psychotropic drug-drug interactions listed in drug monographs.
Liu X; Hatton RC; Zhu Y; Hincapie-Castillo JM; Bussing R; Barnicoat M; Winterstein AG
J Am Pharm Assoc (2003); 2017; 57(6):698-703.e2. PubMed ID: 28844584
[TBL] [Abstract][Full Text] [Related]
11. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
Das B; Rawat VS; Ramasubbu SK; Kumar B
Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions between COVID-19 therapeutics and psychotropic medications.
Cuomo A; Barillà G; Serafini G; Aguglia A; Amerio A; Cattolico M; Carmellini P; Spiti A; Fagiolini A
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):925-936. PubMed ID: 38032183
[TBL] [Abstract][Full Text] [Related]
13. Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.
Chamberlain SR; Baldwin DS
CNS Drugs; 2021 Jul; 35(7):703-716. PubMed ID: 34240393
[TBL] [Abstract][Full Text] [Related]
14. Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil.
Castilho ECD; Reis AMM; Borges TL; Siqueira LDC; Miasso AI
J Psychiatr Ment Health Nurs; 2018 Feb; 25(1):3-13. PubMed ID: 28892271
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
Khan Q; Ismail M; Haider I; Khan F
Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials.
Wiśniowska B; Tylutki Z; Wyszogrodzka G; Polak S
BMC Pharmacol Toxicol; 2016 Mar; 17():12. PubMed ID: 26960809
[TBL] [Abstract][Full Text] [Related]
17. Patients on psychotropic medications and herbal supplement combinations: clinical considerations.
Tang SW; Tang W; Leonard BE
Int Clin Psychopharmacol; 2017 Mar; 32(2):63-71. PubMed ID: 27902536
[TBL] [Abstract][Full Text] [Related]
18. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
[TBL] [Abstract][Full Text] [Related]
19. Clinically relevant drug interactions between anticancer drugs and psychotropic agents.
Yap KY; Tay WL; Chui WK; Chan A
Eur J Cancer Care (Engl); 2011 Jan; 20(1):6-32. PubMed ID: 20030690
[TBL] [Abstract][Full Text] [Related]
20. Oral health impacts of medications used to treat mental illness.
Cockburn N; Pradhan A; Taing MW; Kisely S; Ford PJ
J Affect Disord; 2017 Dec; 223():184-193. PubMed ID: 28759866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
